Publications by authors named "Kenneth B Gordon"

Claim this Profile
B
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
Joseph F Merola, Richard B Warren, Diamant Thaçi, Kenneth B Gordon, Emi Nishida

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
Andrew Blauvelt, Richard G Langley, Mark Lebwohl, Bruce Strober, Richard B Warren, Kenneth B Gordon

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review.
Nicole D Boswell, Alexa Ries, Kenneth B Gordon, Shikha Singla

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current State.
Eric M Ruderman, Kenneth B Gordon

Rheum Dis Clin North Am· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.
Linda Stein Gold, Alice B Gottlieb, April W Armstrong, Theodore Alkousakis, Robert Bissonnette, Kenneth B Gordon

Br J Dermatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.
Kenneth B Gordon, Matthias Augustin, Jonathan Barker, Yayoi Tada, Mark G Lebwohl

J Am Acad Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.
Kenneth B Gordon, Yayoi Tada, Milan J Anadkat, Siew Eng Choon, Boni Elewski

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Kenneth B Gordon

Dermatol Ther (Heidelb)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses.
Kenneth B Gordon, Joseph F Merola, Peter Foley, Olivia Choi, Daphne Chan

J Drugs Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.
Kenneth B Gordon, Yayoi Tada, Milan J Anadkat, Siew Eng Choon, Boni Elewski

Dermatol Ther (Heidelb)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, Patrick J Branigan, Yanqing Chen

J Invest Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
Nicole D Boswell, Shikha Singla, Kenneth B Gordon

Am J Clin Dermatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.
Kenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, Laura C Coates, Filip E Van den Bosch

Dermatol Ther (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.
April W Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E Teneralli, Kenneth B Gordon

Dermatol Ther (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon

J Eur Acad Dermatol Venereol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
April W Armstrong, Matthias Augustin, Jennifer L Beaumont, Tan P Pham, Stacie Hudgens, Kenneth B Gordon

Dermatol Ther (Heidelb)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin

Br J Dermatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
Andrew Blauvelt, Richard G Langley, Kenneth B Gordon, Jonathan I Silverberg, Kilian Eyerich

Dermatol Ther (Heidelb)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Akimichi Morita, Bruce Strober, A David Burden, Siew Eng Choon, Milan J Anadkat, Kenneth B Gordon

Lancet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon

Immunotherapy· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon

J Am Acad Dermatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL 23 biologics for the treatment of plaque psoriasis.
Alan Vu, Caden Ulschmid, Kenneth B Gordon

Expert Opin Biol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deucravacitinib in moderate-to-severe psoriasis.
Alan Vu, Victoria Maloney, Kenneth B Gordon

Immunotherapy· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, Linda Stein Gold

JAMA Dermatol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris

Dermatol Ther (Heidelb)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis